Abstract: The present invention provides methods for the diagnosing, monitoring and prognostication of primary and secondary cardiac disorders in a subject based on lncRNA expression. The invention also provides methods for predicting heart failure after myocardial infarction, and differenciation of Ischemic versus non-ischemic Heart Failure. The assessment/quantification of these lncRNAs may also be used as a marker for monitoring drug-induced cardiac toxicities and for the assessment of cardiac involvement during systemic diseases and others disorders/toxicities impacting cardiac function. These lncRNAs are cardiac tissue enriched and may be involved in different cardiac pathophysiological events and represent a potential target for therapeutical approaches.

Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.

Abstract: According to one embodiment, a primer set for elongating a target short-chain nucleic acid containing a first sequence to obtain an elongated product is provided. The elongated product contains a second, a third, a fourth sequence, a complementary sequence of the 1?-th sequence and a sixth sequence. The complementary sequence of the 1?-th sequence is a loop primer sequence. The primer set contains a first elongation primer containing a first elongation primer sequence and a complementary sequence of the sixth sequence, and a second elongation primer containing a second elongation primer sequence, the fourth, the third, and the second sequence.

Abstract: Provided herein are methods and systems for establishing the presence of a sequence element in nucleic acid molecules. The sequence element may comprise a fused gene, a reporter gene, or another useful sequence for cell and tissue engineering, such as those used for labeling cells, identifying successfully transfected or transduced cells, etc. A method provided herein may additionally allow for barcoding of nucleic acid molecules and analysis of libraries of barcoded nucleic acid molecules.

Abstract: The present disclosure provides methods and systems for processing a nucleotide mixture. A nucleotide mixture can be purified. A nucleotide mixture can be processed for use in nucleic acid synthesis. A nucleotide mixture can be processed for use in nucleic acid sequencing.

Abstract: The invention provides methods for assessment of fetal DNA samples using target-enriched multiplexed parallel analysis. The methods of the invention utilize Target Capture Sequences (TACS) to thereby enrich for target sequences of interest, followed by massive parallel sequencing and statistical analysis of the enriched population. The methods can be used with fetal or embryonic DNA samples, for example for the detection of the presence of genetic abnormalities, e.g., for purposes of IVF Pre-implantation Genetic Screening (PGS) and Diagnosis (PGD). Kits for carrying out the methods of the invention are also provided.

Abstract: The present invention relates to methods of detecting preliminary stages of testicular germ cell tumors, more particularly testicular intraepithelial neoplasia (TIN), in a subject and to the use of miR-371a-3p as a biomarker for the detection of TIN. It further relates to the use of miR-371a-3p-specific primers and/or miR-371a-3p-specific probes and of corresponding kits for the detection of TIN.

Abstract: The invention provides, inter alia, methods for uniquely labeling populations of agents of interest using random combinations of oligonucleotides. The oligonucleotides may comprise a unique nucleotide sequence and/or one or more non-nucleic acid detectable moieties.

Abstract: Disclosed is a hybridisation capture method based on the pyrophosphorolysis reaction. According to the present invention, there is provided a method for increasing the ratio of a first nucleic add sequence to second nucleic add sequence in a sample.

Abstract: Provided herein are methods for isolating nucleic acids from intact cells in a sample of intact cells and cell free nucleic acids. The intact cells and cell free nucleic acids are captured and concentrated within the pores of a silicate matrix in a microporous silicate filter. Within the silicate matrix the cell free nucleic acids are degraded with a nuclease, the intact cells are lysed with the released DNA binding to the silicate, the nuclease treated cell free nucleic acids and contaminants from the lysed are washed from the silicate matrix and the DNA bound to the silicate is eluted therefrom to form an isolated DNA product.

Abstract: The object of the invention is a method of detecting genetic material in a biological sample in which the biological sample is loaded into the reaction cartridge (6) and then the reaction cartridge (6) is placed in the control device, the collected biological sample is taken to the isolation chamber (7), isolation of biological material from the tested sample by heating the isolation chamber (7), the isolated genetic material is moved into a plurality of reaction chambers (8.1, 8.2, 8.3, 8.4), genetic material is amplified by heating the reaction chambers (8.1, 8.2, 8.3, 8.4), lyophilized reagents for genetic material amplification together with lyophilized fluorescent tag intercalating with genetic material are present in the reaction chambers (8.1, 8.2, 8.3, 8.4), and signal detection from fluorescent tags is carried out along with the genetic material amplification stage.

Abstract: A method providing next generation sequencing (NGS)-based high-resolution HLA typing as a routine clinical test. The method uses a multiplex PCR primer design for amplifying multiple human leukocyte antigen (HLA) Class I and Class II genes in a single reaction for NGS. The test quality is improved and the protocol for typing multiple HLA genes is simplified because the number of amplification reactions are reduced nearly 10-fold, to yield a substantially equimolar ratio of individual HLA gene amplification products. The invention eliminates an amplicon pooling step, reducing the reagent cost, and required sample DNA quantity.

Abstract: This disclosure provides methods and systems useful in array-based analysis of mixed nucleic acid populations, including for multiplex genotyping of a mixed nucleic acid sample and for detecting differences in copy number of a target polynucleotide and/or a target chromosome (e.g., microdeletions, duplications and aneuploidies). The disclosure also provides methods and systems useful in the diagnosis of genetic abnormalities in a mixed nucleic acid population taken non-invasively from an organism, such as a sample of blood, plasma, serum, urine stool or saliva. The disclosed methods and systems find use in multiple applications, including prenatal testing and cancer diagnostics. The disclosure is based on the hybridisation of amplified fragments from the sample, e.g. a maternal sample, which may employ molecular inversion probes MIP to an oligonucleotide array and the detection of the alleles based on different signals from the different alleles of the SNP.

Abstract: This invention provides methods of amplifying genomic DNA to obtain an amplified representative population of genome fragments. Methods are further provided for obtaining amplified genomic DNA representations of a desired complexity. The invention further provides methods for simultaneously detecting large numbers of typable loci for an amplified representative population of genome fragments. Accordingly the methods can be used to genotype individuals on a genome-wide scale.

Abstract: The present disclosure provides methods and systems for sequencing nucleic acid molecules using a single frequency during detection, or fewer frequencies than types of nucleotide bases identified during detection. Methods and systems of the present disclosure may involve transiently binding nucleotides. Methods and systems provided herein may enable sequences to be determined at a higher accuracy and efficiency.

Abstract: The present invention relates to a method of selectively amplifying at least one nucleic acid sequence of at least one microorganism and/or virus in a sample of a subject, wherein k-mers 3 are applied that show a difference in frequency and/or context in the genome 2 of the at least one microorganism and/or virus compared to the genome of the subject 1.

Abstract: The present invention pertains to: an oligonucleotide preservation method; and a kit comprising an oligonucleotide. The present invention provides a method for stably preserving an oligonucleotide-containing solution by adding a nucleic acid-binding protein to said oligonucleotide-containing solution in advance.

Abstract: The invention is directed to modified oligonucleotide compositions and methods for selectively reducing unwanted nucleic acid contaminants and enriching for desired nucleic acid targets from complex genomic nucleic acid mixtures for sequencing applications. The modified oligonucleotide compositions include one or more modified groups that increase the Tm of the resultant oligonucleotide composition.

Abstract: The invention is directed to modified oligonucleotide compositions and methods for selectively reducing unwanted nucleic acid contaminants and enriching for desired nucleic acid targets from complex genomic nucleic acid mixtures for sequencing applications. The modified oligonucleotide compositions include one or more modified groups that increase the Tm of the resultant oligonucleotide composition.

Abstract: The present invention provides a method of quantification of a target nucleic acid, using at least any two of the genes SYT10, EPHA3, PLEKHF1 and KBTBD4 as control genes. In particular, the combination of the genes SYT10, EPHA3, PLEKHF1 and KBTBD4, known as the 4Plex, is provided as a control for nucleic acid quantification. The 4Plex has particular utility as a control for nucleic acid quantification by methylation-specific droplet digital PCR.